No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
SG Stock MarketDetailed Quotes
583 Progen
- 0.034
- +0.001+3.03%
10min DelayNot Open Jun 26 10:58 CST
13.28MMarket Cap5.67P/E (TTM)
0.034High0.034Low10.00KVolume0.034Open0.033Pre Close340.00Turnover0.05052wk High0.01%Turnover Ratio390.51MShares0.03252wk Low0.006EPS TTM3.33MFloat Cap0.228Historical High8.50P/E (Static)98.04MShs Float-0.006Historical Low0.004EPS LYR0.00%Amplitude--Dividend TTM0.49P/B100Lot Size--Div YieldTTM
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Rani Therapeutics: Co, Progen to Share Responsibilities for Rt-114, Including 50/50 Cost & Revenue Share
Express News | Rani & Progen Partnership With No Upfront Payment
Express News | Rani Therapeutics & Progen Co-Develop Rt-114
Rani Therapeutics Has Entered Into A Definitive Agreement With ProGen For The Co-development And Commercialization Of RT-114, An Oral Ranipill Capsule Containing ProGen's PG-102, A GLP-1/GLP-2 Dual Agonist, For Obesity
Under the terms of the collaboration agreement, Rani and ProGen agree to share responsibilities for the development and commercialization of RT-114 worldwide, including a 50/50 cost and revenue share
Express News | Rani Therapeutics Announces Partnership With Progen on Development of Oral Obesity Treatment
Progen Holdings Announces Board Revamp
Comments
$Progen(583.SG$ poor financial results very difficult to rise
$Progen(583.SG$ I said already will fall now falling
$Progen(583.SG$ poor financial results will fall further
$Progen(583.SG$ I said fall already now falling will fall further chart bearish
$Progen(583.SG$ chart turn bearish will fall
Read more
Analysis
Price Target
No Data
Heat List
SG
Overall
Symbol
Latest Price
%Chg